First proctological synbiotic



About the product:
ProctoLact-M® is the first probiotic selected for health supporting in proctologic diseases.

ProctoLact-M® contains a live strain of probiotic bacteria Lactobacillus rhamnosus PL1 which was isolated from the gastrointestinal tract of a healthy newborn. The L. rhamnosus PL1 strain effectively inhibits the multiplication
of pathogenic bacteria which are a frequent cause of inflammations in the anus and the rectum, as well as perianal wounds. Thanks to the colonization of the large intestine and the rectum, ProctoLact-M® restores the correct microflora of the terminal part of the gastrointestinal tract, supporting treatment of inflammations of the rectum and, at the same time, preventing other infections.

This product is recommended for dietary purposes in the following conditions:
restoration, proliferation and maintenance of normal microflora of colon (rectum and anus) by inhibition of pathogenic strains, and supply of natural bacterial strain,
as prophylaxis and support of treatment of inflammation and ulceration occurring in anal mucosa, perianal wounds, fistulas and fissures,
as prophylaxis and support of treatment of inflammation and ulceration due to recurrent hemorrhoids,
as prophylaxis prior to surgery of rectum or anus,
as prophylaxis of other conditions that could increase a risk of colon infections, during and after use of antibiotics.

Active substance:
Lactobacillus rhamnosus PL1 – lyophilisate (~2 x 109 CFU/2g),
inulin 500 mg/2g

10 and 30 sachets; each sachet contains 2 g of powder

Type of product:
dietary food for special medical purposes (DFSMP)